Statin therapy and neuropathy in type 1 diabetes: A cross‐sectional study
Authors' conclusion
This study demonstrates that individuals with T1DM exhibit neuropathic symptoms and disability, increased vibration perception thresholds, corneal nerve fibre loss and evidence of CAN. However, statin therapy was associated with comparable measures of DPN and CAN, despite statin-treated patients having a longer duration of diabetes and a higher BMI.
Study context
- Population
- Participants with T1DM and healthy controls evaluated for diabetic peripheral neuropathy (DPN), cardiac autonomic neuropathy (CAN) and corneal confocal microscopy (CCM)
- Participants
- 68 / 92 / 64
- Exposure
- Statin-treated vs non-statin T1DM vs healthy controls
- Non-statinn = 68
- Statin treatedn = 92
- Healthy controlsn = 64reference
- Outcome
- Neuropathy measures (non-statin vs statin vs healthy controls)
Main finding
As reported in the abstract
- DNS: 0.49 ± 0.14 vs 0.90 ± 0.13 vs 0.15 ± 0.13
- p < 0.001
- Neuropathy disability score (NDS): 2.55 ± 0.29 vs 3.67 ± 0.26 vs 0.44 ± 0.28
- p < 0.001
- Vibration perception threshold: 13.68 ± 1.16 vs 16.03 ± 1.03 vs 6.05 ± 1.08
- p < 0.001
- Corneal nerve fibre density: 19.61 ± 1.04 vs 19.02 ± 0.92 vs 28.48 ± 0.97
- p < 0.001
- Corneal nerve branch density: 20.40 ± 2.21 vs 21.39 ± 1.94 vs 37.31 ± 2.05
- p < 0.001
- Corneal nerve fibre length: 11.97 ± 0.51 vs 11.51 ± 0.45 vs 16.55 ± 0.47
- p < 0.001
- DB-HRV: 26.27 ± 1.76 vs 24.21 ± 1.51 vs 30.18 ± 1.67
- p = 0.033
- 30:15 ratio: 1.32 ± 0.04 vs 1.21 ± 0.03 vs 1.15 ± 0.07
- p = 0.033
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Statin vs non-statin T1DMBetween Statin treated and Non-statin | DNS p = 0.04 |
| Statin vs non-statin T1DMBetween Statin treated and Non-statin | NDS p = 0.009 |
| Statin vs non-statin T1DMBetween Statin treated and Non-statin | 30:15 ratio p = 0.04 |
- Statin vs non-statin T1DM — Statin group older
- p < 0.001
- Statin vs non-statin T1DM — Statin group higher BMI
- p = 0.001
- Statin vs non-statin T1DM — Statin group longer DM duration
- p < 0.001
Statin vs non-statin T1DM
- No significant differences in most neuropathy measures
Original publication
Statin therapy and neuropathy in type 1 diabetes: A cross‐sectional study. Diabetes Obes Metab. Published 24 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →